<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716924</url>
  </required_header>
  <id_info>
    <org_study_id>L_9317</org_study_id>
    <nct_id>NCT00716924</nct_id>
  </id_info>
  <brief_title>CASTLE (Clopidogrel And Serum Troponin Level Elevation)</brief_title>
  <acronym>CASTLE</acronym>
  <official_title>Clopidogrel 600 mg and 300 mg as a Loading Dose Prior to Percutaneous Coronary Intervention And Serum Troponin Level Elevation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To test if 600 mg of clopidogrel loading dose administered ≥ 6 and ≤ 24
      hours prior to PCI produce a greater decrease of periprocedural release of biochemical
      markers (CK, CK-MB, and troponin-T and/or I) of myocardial necrosis, compared to 300 mg
      loading dose, given ≥ 6 and ≤ 24 hours prior to PCI or 600 mg loading dose of clopidogrel,
      administered immediately (≤ 45 minutes) before PCI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-percutaneous coronary intervention elevation of troponin T.</measure>
    <time_frame>At 6 and 12 months post-PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events.</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard hematology and blood chemistry.</measure>
    <time_frame>At 6 and 12 months post-PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>300 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>600 mg</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having symptomatic coronary artery disease with objective evidence of
             ischemia (eg, symptoms of angina pectoris, positive stress test results or dynamic
             electrocardiographic (ECG) changes).

          -  Patients undergoing stent implantation

        Exclusion Criteria:

          -  Any known contraindication to the use of aspirin or clopidogrel.

          -  Patients receiving clopidogrel within 10 days, thrombolytics within 24 hours or
             receiving oral anticoagulation therapy

          -  Elective administration of IIb/IIIa inhibitors.

          -  Cardiogenic shock

          -  Acute MI&lt; 24 hours

          -  BP systolic &lt;100 mmHg

          -  Left ventricular ejection fraction &lt; 30%

          -  Heart failure, NYHA class III or IV

          -  Severe renal insufficiency (creatinine &gt; 3.0 mg/dL)

          -  Platelet count &lt;100,000/mm³

          -  Target lesion in a venous bypass graft

          -  Target lesion in a chronic occlusion

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Diaz, Md</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi aventis administrative office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

